drugset / Trial / NCT01469156
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
RandomizedSingle-groupDouble-blindTreatment
Summary
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month of drug safety follow up in subjects with exudative polypoidal choroidal vasculopathy (PCV) for a total of 24 months.
Timeline
- Start
- 2011-09
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 1 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |